Table 1.

Selected EULAR recommendations concerning the use of bDMARDs and tsDMARDs during pregnancy

Drug	Recommendations
Infliximab	Therapy can be continued up to week 20 of pregnancy
Adalimumab	If indicated, it can be used throughout pregnancy
Etanercept	Therapy can be continued up to week 30–32 of pregnancy If indicated, it can be used throughout pregnancy
Certolizumab	Therapy can be continued throughout pregnancy
Golimumab	Insufficient evidence to support the use of the medication
Rituximab	It can be used in early stages of pregnancy in exceptional cases The use of the medication in later stages of pregnancy may result in decreased b cell levels and other types of cytopenia in the newborn
Tocilizumab Abatacept Anakinra Ustekinumab Belimumab	Insufficient evidence regarding the drug’s safety during pregnancy Treatment should be altered before the pregnancy May be used only if no other, safer options allow for adequate management of disease activity in the mother
Tofacitinib	Should be discontinued before conception Insufficient data concerning safety during pregnancy